Integral Diagnostics Hisse

Integral Diagnostics EBITDA

Integral Diagnostics (IDX.AX) öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 17 Ağu 2026 itibarıyla 114,83 M AUD dir. Önceki yılda, EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) 89,03 M AUD idi — 28,97% (daha yüksek) bir değişiklik.

EBITDA

114,83 MAUD

YoY

28,97%

Son güncelleme:

Integral Diagnostics öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 114,83 M AUD dir. Integral Diagnostics öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2025 89,03 M AUD idi. %28,97 daha yüksek önceki yıla kıyasla azalmaktadır.
Access this data via the Eulerpool API

Integral Diagnostics Hisse senedi analizi

Integral Diagnostics ne yapar? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics, Eulerpool'daki en popüler şirketlerden biridir.

Integral Diagnostics hisse senedi hakkında sık sorulan sorular

Integral Diagnostics şirketinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 yılında 114,83 M AUD.

Integral Diagnostics öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 89,03 M AUD değerinden 114,83 M AUD değerine değişmiş ve bu %28,97 değişimi temsil etmektedir. Değer önceki yıldan daha yüksek dir.

Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) öğesinin Integral Diagnostics değerinin 2006'dan itibaren tam tarihsel gelişimini bulabilirsiniz — yıllık değerler, grafikler ve ayrıntılı analiz ile.

EBITDA, finansal yapı, vergi ortamı ve nakit olmayan amortisman giderleri etkisinden önceki işletme performansını ölçer.

EBITDA = EBIT + Amortisman

EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin AUD, yatırımcılar için kilit bir faktördür. Bu metrikte yapılan değişiklikler temel faktörlerin iyileşmesini veya kötüleşmesini gösterebilir ve hisse senedi fiyatını doğrudan etkiler. Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin Integral Diagnostics değerini tarihsel olarak ve gerçek zamanlı olarak takip edebilirsiniz.

Access this data via the Eulerpool API

Gelir Tablosu — Integral Diagnostics

Tüm Kilit Metrikler — Integral Diagnostics